The authors designed a clinical trial to assess the impact of aspirin (ASA) (600 mg four times daily) on the constitutional sequelae of recombinant leakocyte A interferon (IFN‐α2A), 20 × 106 U/m2 thrice weekly, in 29 patients with advanced renal cell cancer (RCC). Aspirin provided no meaningful amelioration of side effects compared to our prior experience of IFN‐α2A alone. Interestingly, the objective response rate of 34% (10/29) was considerably higher than the 15% recently reported from an aggregate of 344 patients participating in 14 prospective clinical trials. In light of small numbers, subtle selection biases, and the well‐recognized hazards of retrospective analyses, currently it is unclear if the apparent therapeutic advantage from ASA plus IFN‐α2A reflects chance occurrence or therapeutic potentiation from ASA. A randomized trial is planned to determine if ASA may have enhanced the efficacy of IFN‐α2A in patients with advanced RCC.
|Original language||English (US)|
|Number of pages||5|
|State||Published - May 1 1988|
ASJC Scopus subject areas
- Cancer Research